Search results for "Percutaneous"

showing 10 items of 471 documents

Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation

2019

Background: Appropriate antithrombotic regimens for patients with atrial fibrillation who have an acute coronary syndrome or have undergone percutaneous coronary intervention (PCI) are unclear. Methods: In an international trial with a two-by-two factorial design, we randomly assigned patients with atrial fibrillation who had an acute coronary syndrome or had undergone PCI and were planning to take a P2Y12 inhibitor to receive apixaban or a vitamin K antagonist and to receive aspirin or matching placebo for 6 months. The primary outcome was major or clinically relevant nonmajor bleeding. Secondary outcomes included death or hospitalization and a composite of ischemic events. Results: Enroll…

Malemedicine.medical_specialtyAcute coronary syndromeVitamin KPyridonesmedicine.medical_treatmentMEDLINEHemorrhage030204 cardiovascular system & hematologylaw.invention03 medical and health sciencesPercutaneous Coronary Intervention0302 clinical medicinePharmacotherapyDouble-Blind MethodRandomized controlled triallawInternal medicineAtrial FibrillationAntithromboticmedicineHumans03.02. Klinikai orvostancardiovascular diseases030212 general & internal medicineAcute Coronary SyndromeAgedAged 80 and overAspirinbusiness.industryatrial fibrillation ; anticoagulant therapy ; acute coronary syndrome ; apixabanAnticoagulantsPercutaneous coronary interventionAtrial fibrillationGeneral MedicineMiddle Agedmedicine.diseaseConventional PCIPurinergic P2Y Receptor AntagonistsCardiologyPyrazolesDrug Therapy CombinationFemalebusinessPlatelet Aggregation InhibitorsFactor Xa InhibitorsNew England Journal of Medicine
researchProduct

Outcome of extracorporeal membrane oxygenation support for high-risk percutaneous coronary intervention in non-ST-segment elevation acute coronary sy…

2020

Malemedicine.medical_specialtyAcute coronary syndromemedicine.medical_treatmentHemorrhageComorbidityRisk AssessmentSeverity of Illness IndexRussiaVentricular Dysfunction LeftText miningExtracorporeal Membrane OxygenationPercutaneous Coronary InterventionPostoperative Complicationscoronary intervention non-ST-segment elevation acute coronary syndromeInternal medicinemedicineExtracorporeal membrane oxygenationST segmentHumansNon-ST Elevated Myocardial InfarctionAgedbusiness.industryPatient SelectionPercutaneous coronary interventionGeneral Medicinemedicine.diseaseSurvival AnalysisOutcome and Process Assessment Health CareCoronary OcclusionCardiologyextracorporeal membrane oxygenation high-risk percutaneouFemaleRisk AdjustmentCardiology and Cardiovascular MedicinebusinessJournal of cardiovascular medicine (Hagerstown, Md.)
researchProduct

Incidence, Predictors, and Impact on Six-Month Mortality of Three Different Definitions of Contrast-Induced Acute Kidney Injury After Coronary Angiog…

2017

We assessed incidence, predictors, and impact on 6-month mortality of contrast-induced acute kidney injury (CI-AKI) after coronary angiography with or without percutaneous coronary intervention in patients with acute coronary syndrome (ACS), according to 3 different CI-AKI definitions. Serum creatinine (sCr) was assessed at baseline and 48 to 72 hours after procedure to classify patients into 3 CI-AKI groups: Group 1: increase in sCR ≥25% over baseline but absolute increase 25% in the remaining 844 (84.2%). CI-AKI was significantly associated with 6-month all-cause mortality using the definitions for Group 2 (hazard ratio 3.1, 95% confidence interval [CI] 1.5 to 6.6, p = 0.002) and Group 3 …

Malemedicine.medical_specialtyAcute coronary syndromemedicine.medical_treatmentPopulationRenal functionContrast Media030204 cardiovascular system & hematologyCoronary Angiography03 medical and health sciences0302 clinical medicinePercutaneous Coronary InterventionRisk FactorsInternal medicineCause of DeathmedicineRisk of mortalityHumans030212 general & internal medicineAcute Coronary SyndromeMortalityeducationAgededucation.field_of_studybusiness.industryIncidenceHazard ratioAcute kidney injuryPercutaneous coronary interventionAcute Kidney InjuryMiddle Agedmedicine.diseaseConfidence intervalCreatinineCardiologyST Elevation Myocardial InfarctionFemaleCardiology and Cardiovascular MedicinebusinessGlomerular Filtration RateThe American journal of cardiology
researchProduct

Radiation exposure in biliary procedures performed to manage anastomotic strictures in pediatric liver transplant recipients: comparison between radi…

2013

The aim of this study was to estimate radiation exposure in pediatric liver transplants recipients who underwent biliary interventional procedures and to compare radiation exposure levels between biliary interventional procedures performed using an image intensifier-based angiographic system (IIDS) and a flat panel detector-based interventional system (FPDS). We enrolled 34 consecutive pediatric liver transplant recipients with biliary strictures between January 2008 and March 2013 with a total of 170 image-guided procedures. The dose-area product (DAP) and fluoroscopy time was recorded for each procedure. The mean age was 61 months (range 4–192), and mean weight was 17 kg (range 4–41). The…

Malemedicine.medical_specialtyAdolescentmedicine.medical_treatmentConstriction PathologicAnastomosisPercutaneous transhepatic cholangiographyRadiation DosageRadiography InterventionalPediatricsFlat panel detectorlaw.inventionCatheterizationCholangiographyArteriovenous Shunt SurgicallawmedicineFluoroscopyHumansRadiology Nuclear Medicine and imagingChildPediatric Liver Transplantmedicine.diagnostic_testbusiness.industryUltrasoundImage intensifierRadiation ExposureLiver TransplantationRadiation exposureRadiographic Image EnhancementChild PreschoolFluoroscopyFemaleRadiologyCardiology and Cardiovascular MedicinebusinessAngioplasty BalloonCholangiographyCardiovascular and interventional radiology
researchProduct

Percutaneous antegrade electropapillotomy. Study in dogs.

1984

Antegrade electropapillotomy using the percutaneous transcystic approach was successfully performed in 11 of 16 dogs. When the intervention was effective, the pressure gradient between common bile duct and duodenum decreased from 6 to 1.3 mm Hg on average and returned to gradients slightly below the initial values after 4 weeks, owing to reactivation of the sphincter mechanism. Ineffective cutting, however, resulted in a temporary pressure rise. In one dog a papillary stenosis developed and was relieved by antegrade electrocutting. Irrespective of the success of the papillotomy, rises in levels of serum glutamine oxaloacetic and pyruvic transaminase, alkaline phosphatase, serum amylase and …

Malemedicine.medical_specialtyAmpulla of VaterPercutaneousDuodenumElectrosurgeryCholangiographyDogsPressureMedicineAnimalsRadiology Nuclear Medicine and imagingAspartate AminotransferasesCommon Bile DuctCommon bile ductmedicine.diagnostic_testbusiness.industryHepatobiliary diseaseAlanine Transaminasemedicine.diseaseAlkaline PhosphataseSurgeryMajor duodenal papillaRadiographymedicine.anatomical_structureAmylasesDuodenumSphincterFemalePapillary stenosisCardiology and Cardiovascular MedicinebusinessCardiovascular and interventional radiology
researchProduct

Contrast-induced Nephropathy after Percutaneous Coronary Intervention in Simple Lesions: Risk Factors and Incidence are Affected by the Definition Ut…

2011

Aim To compare the incidence, and risk factors, in-hospital and at the 18-month prognosis of contrast-induced nephropathy (CIN) according to the definition utilized: as an increase in serum creatinine (Scr) ≥0.5 mg/dL (CIN 1) or as an increase in Scr ≥25% above baseline values (CIN 2). Methods and Results We prospectively evaluated CIN according to two different definitions in 150 patients who underwent percutaneous coronary intervention (PCI) in simple lesions employing a low-medium dose of contrast media. Incidence of CIN was higher using the CIN 2 definition than CIN 1 (9.3% vs. 4%; p=0.0133). Patients with CIN 1 had a higher incidence of chronic kidney disease (CKD) (66.7% vs. 13.9%; p=…

Malemedicine.medical_specialtyAnemiamedicine.medical_treatmentContrast-induced nephropathyUrologyContrast MediaRenal functionurologic and male genital diseasesPercutaneous coronary interventionNephropathychemistry.chemical_compoundContrast induced nephropathyRisk FactorsInternal MedicinemedicineHumansProspective StudiesAngioplasty Balloon CoronaryRenal Insufficiency ChronicneoplasmsAgedCreatininecontrast induced nephropathy percutaneous coronary interventionbusiness.industryIncidenceIncidence (epidemiology)virus diseasesPercutaneous coronary interventionAnemiaGeneral MedicineMiddle Agedmedicine.diseasefemale genital diseases and pregnancy complicationsSurgerysurgical procedures operativeItalychemistryCreatinineFemaleKidney DiseasesbusinessKidney diseaseInternal Medicine
researchProduct

Effect of tirofiban on percutaneous coronary intervention-induced endothelial dysfunction in patients with stable coronary artery disease

2004

Recent studies demonstrated that glycoprotein (GP) IIb/IIIa receptor antagonists improve endothelial dysfunction of forearm resistance vessels in patients with stable coronary artery disease. However, it remains unclear whether these findings can be extended to the conductance vessel level. In this study, we aimed to evaluate the acute effect of tirofiban on endothelial function of arterial conductance vessels in patients undergoing percutaneous coronary intervention (PCI). Endothelial function was examined by ultrasonographic measurement of flow-mediated vasodilation (FMD) of the brachial artery. Endothelium-independent vasodilation was determined in response to nitroglycerin. Sixty-six pa…

Malemedicine.medical_specialtyBrachial ArteryEndotheliummedicine.medical_treatmentCoronary Artery DiseasePlatelet Glycoprotein GPIIb-IIIa ComplexCoronary artery diseaseAngioplastymedicine.arteryInternal medicinemedicineHumanscardiovascular diseasesEndothelial dysfunctionBrachial arteryAgedbusiness.industryPercutaneous coronary interventionTirofibanmedicine.diseasemedicine.anatomical_structureTirofibanConventional PCIcardiovascular systemCardiologyTyrosineFemaleEndothelium VascularCardiology and Cardiovascular Medicinebusinessmedicine.drugThe American Journal of Cardiology
researchProduct

Hepatocellular cancer response to radiofrequency tumor ablation: contrast-enhanced ultrasound

2007

Radiofrequency ablation (RFA) is increasingly being used as percutaneous treatment of choice for patients with early stage hepatocellular carcinoma (HCC). An accurate assessment of the RFA therapeutic response is of crucial importance, considering that a complete tumor ablation significantly increases patient survival, whereas residual unablated tumor calls for additional treatment. Imaging modalities play a pivotal role in accomplishing this task, but ultrasound (US) is not considered a reliable modality for the evaluation of the real extent of necrosis, even when color/power Doppler techniques are used. Recently, newer microbubble-based US contrast agents used in combination with grey-sca…

Malemedicine.medical_specialtyCarcinoma HepatocellularPercutaneousRadiofrequency ablationUrologymedicine.medical_treatmentSulfur HexafluorideContrast MediaCatheter ablationSensitivity and Specificitylaw.inventionImaging Three-DimensionallawHumansMedicineRadiology Nuclear Medicine and imagingStage (cooking)PhospholipidsUltrasonography InterventionalAgedAged 80 and overRadiological and Ultrasound Technologybusiness.industryLiver NeoplasmsUltrasoundGastroenterologyGeneral MedicineRadiofrequency ablationcontrast-enhanced ultrasound hepatocellular carcinomamedicine.diseaseTreatment OutcomeHepatocellular carcinomaCatheter AblationDisease ProgressionMicrobubblesFemaleRadiologybusinessContrast-enhanced ultrasoundAbdominal Imaging
researchProduct

Percutaneous Radiofrequency Ablation for Hepatocellular Carcinoma Before Liver Transplantation: A Prospective Study with Histopathologic Comparison

2006

OBJECTIVE. The aims of this study were to determine the feasibility and efficacy of percutaneous radiofrequency ablation in patients with hepatocellular carcinoma waiting for liver transplantation and to compare the radiologic and pathologic findings. SUBJECTS AND METHODS. Twenty-six patients with 35 hepatocellular carcinomas were addressed for transplantation. Complications of the procedures were recorded. Primary and secondary technique effectiveness and causes of exclusion from the waiting list were assessed. After transplantation, tumor recurrence was evaluated for at least 1 year in all patients. Radiologic-pathologic comparison of the explant was performed. RESULTS. Percutaneous radio…

Malemedicine.medical_specialtyCarcinoma HepatocellularPercutaneousRadiofrequency ablationmedicine.medical_treatmentLiver transplantationlaw.inventionlawPreoperative CaremedicineHumansRadiology Nuclear Medicine and imagingProspective StudiesProspective cohort studyablation cancer hepatocellular carcinoma liver transplantation radiofrequencybusiness.industryLiver NeoplasmsCancerGeneral MedicineMiddle Agedmedicine.diseaseAblationLiver TransplantationSurgeryRadiographyTransplantationHepatocellular carcinomaCatheter AblationFeasibility StudiesFemaleRadiologybusinessFollow-Up StudiesAmerican Journal of Roentgenology
researchProduct

Reduced Rivaroxaban Dose Versus Dual Antiplatelet Therapy After Left Atrial Appendage Closure: ADRIFT a Randomized Pilot Study.

2020

Background: Percutaneous left atrial appendage closure (LAAC) exposes to the risk of device thrombosis in patients with atrial fibrillation who frequently have a contraindication to full anticoagulation. Thereby, dual antiplatelet therapy (DAPT) is usually preferred. No randomized study has evaluated nonvitamin K antagonist oral anticoagulant after LAAC, and we decided to evaluate the efficacy and safety of reduced doses of rivaroxaban after LAAC. Methods: ADRIFT (Assessment of Dual Antiplatelet Therapy Versus Rivaroxaban in Atrial Fibrillation Patients Treated With Left Atrial Appendage Closure) is a multicenter, phase IIb study, which randomized 105 patients after successful LAAC to eith…

Malemedicine.medical_specialtyCardiac CatheterizationPercutaneousTime FactorsAntithrombin IIIAtrial AppendagePilot Projects030204 cardiovascular system & hematologyFibrin Fibrinogen Degradation Products03 medical and health sciences0302 clinical medicineFibrinolytic AgentsRivaroxabanLeft atrialHeart RateInternal medicineAtrial FibrillationMedicineHumansAtrial Appendage030212 general & internal medicineContraindicationBlood CoagulationAgedAppendageAged 80 and overRivaroxabanbusiness.industryDual Anti-Platelet TherapyAtrial fibrillationThrombosisClopidogrelmedicine.diseasePeptide Fragments3. Good healthTreatment OutcomeCardiologyAtrial Function LeftFemaleProthrombinFranceCardiology and Cardiovascular MedicinebusinessBiomarkersPlatelet Aggregation Inhibitorsmedicine.drugFactor Xa InhibitorsPeptide HydrolasesCirculation. Cardiovascular interventions
researchProduct